Uroquant

Executive Summary

UroQuant Diagnostics is a German medtech company developing a non-invasive, mass spectrometry-based urine test for the early detection of bladder cancer. Unlike current standard-of-care cystoscopy, which is invasive, costly, and burdensome to patients, UroQuant's method identifies bladder cancer-specific biomarker proteins in a simple urine sample. This approach promises high sensitivity and specificity, potentially enabling earlier diagnosis, reducing recurrence monitoring costs, and improving patient compliance. Founded in 2017 and based in Munich, the company targets the large and growing bladder cancer diagnostics market, driven by aging populations and increased screening awareness. While still in development, UroQuant's technology could become a valuable triage tool, reducing unnecessary cystoscopies and enabling faster treatment decisions. The company is actively pursuing regulatory approvals and clinical validation to bring its test to clinical use.

Upcoming Catalysts (preview)

• Q4 2026CE marking under EU IVDR60% success
• Q2 2026Publication of pivotal clinical validation study in peer-reviewed journal70% success
• Q3 2026Strategic partnership with leading urology clinic network for multicenter study50% success